You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, November 2013
|
| DOI | 10.1186/1750-1172-8-180 |
| Pubmed ID | |
| Authors |
Garret Kent Fellows, Aidan Hollis |
| Abstract |
Manufacturers justify the high prices for orphan drugs on the basis that the associated R&D costs must be spread over few patients. The proliferation of these drugs in the last three decades, combined with high prices commonly in excess of $100,000 per patient per year are placing a substantial strain on the budgets of drug plans in many countries. Do insurers spend a growing portion of their budgets on small patient populations, or leave vulnerable patients without coverage for valuable treatments? We suggest that a third option is present in the form of a cost-based regulatory mechanism. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 7% |
| Canada | 1 | 7% |
| Mexico | 1 | 7% |
| United States | 1 | 7% |
| United Kingdom | 1 | 7% |
| Unknown | 10 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 60% |
| Scientists | 6 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 3% |
| Unknown | 65 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 21% |
| Student > Master | 10 | 15% |
| Student > Doctoral Student | 8 | 12% |
| Student > Bachelor | 7 | 10% |
| Student > Ph. D. Student | 5 | 7% |
| Other | 12 | 18% |
| Unknown | 11 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 15% |
| Social Sciences | 9 | 13% |
| Economics, Econometrics and Finance | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Other | 13 | 19% |
| Unknown | 12 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2019.
All research outputs
#2,614,443
of 25,373,627 outputs
Outputs from Orphanet Journal of Rare Diseases
#336
of 3,105 outputs
Outputs of similar age
#21,992
of 207,730 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#7
of 43 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,730 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.